Journal
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
Volume 17, Issue 10, Pages 2603-2608Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1055-9965.EPI-07-2766
Keywords
-
Funding
- Danish Rheumatism Association
- Direkto Jens Aage Sorensen og Hustru Edith Ingeborg Sorensens Mindefond
- The Aase and Ejnar Danielsen Fund
- The Kornerup Fund
- The Danish Cancer Society
Ask authors/readers for more resources
Serum YKL-40 is a potential biomarker of prognosis in cancer patients, but assessment of serum YKL-40 requires knowledge of its normal variation. In this study, we evaluated diurnal, weekly, and long-term variation in serum YKL-40 in healthy subjects using a commercial ELISA. The intra-assay coefficient of variation was <= 5.0% and interassay <= 10.2%. Systematic changes in diurnal measurements of serum YKL-40 could not be shown. Physical exercise for 20 min had no effect on serum YKL-40. The within-subject coefficient of variation, including variation over time and interassay, was 28.8% and 30.2% over a period of 2 and 3 years, and the intraclass correlation coefficients were 72.4% and 72.2%, indicating reasonable reliability of serum YKL-40 measurements. The 95% confidence limits for the difference between two measurements (same subject), including interassay variation, were a 52% reduction and a 109% increase in serum YKL-40. These studies show that relatively small variation is found in serum YKL-40 in healthy subjects. However, a single measurement of serum YKL-40 from an individual may not have a propnostic value, and serum YKL-40 alone cannot be a good biomarker for cancer because serum YKL-40 can be elevated in patients with other diseases characterized by inflammation and tissue remodeling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available